ArticleBone marrow transplantation2023
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Abstract readLetter
In one paragraph
Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.Nature medicine · 2026Article
- Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy.World journal of experimental medicine · 2026Article
- Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.Bone marrow transplantation · 2026Article
- Article
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience.Bone marrow transplantation · 2025Article
- Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.Immunotherapy · 2025Review
- Receiving CAR T-cells gets faster, but not for all in need.Blood advances · 2025Article
- Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- CAR-T cell manufacturing: Major process parameters and next-generation strategies.The Journal of experimental medicine · 2024Review
- Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.Frontiers in immunology · 2024Review
- The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.Hematology/oncology clinics of North America · 2023Review
- Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.Transplantation and cellular therapy · 2023Article
- Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.Cancer management and research · 2023Review
- "Waitlist mortality" is high for myeloma patients with limited access to BCMA therapy.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Samer Al HadidiMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. salhadidi@uams.edu.ORCID 0000-0003-4297-8042
Aniko SzaboBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-8129-0614
Jean EsselmannBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Lindsay HammonsBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Munawwar HussainMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Yetunde OgunsesanMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Nishanth ThalambeduMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Fatima KhanMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jaskirat SethiMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Abhishek JanardanBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Sabarinath Venniyil RadhakrishnanBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Sharmilan ThanendrarajanMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Carolina SchinkeMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0002-2699-1741
Binod DhakalBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Siegfried JanzBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-2229-5511
Saurabh ChhabraDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic, Rochester, AZ, USA.ORCID 0000-0001-9117-8696
Anita D'SouzaBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-1092-5643
Maurizio ZangariMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Frits van RheeMyeloma Center, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0001-9959-1282
Meera MohanBone Marrow Transplant Service, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. memohan@mcw.edu.ORCID 0000-0002-6913-6526
Funding
Defining genetic pathways of plasma-cell neoplasiaR01CA151354 · NCI · UNIVERSITY OF IOWA · PI JANZ, SIEGFRIED · 2010 to 2022
$3.9MAbstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenHumansImmunotherapy, AdoptivePatientsB-Cell Maturation AntigenReceptors, Chimeric Antigen
Identifiers
PMID
36550200What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.